Back to Journals » Clinical Ophthalmology » Volume 4

Hypoperfusive and hypertensive ocular manifestations in Takayasu arteritis

Authors Peter J, David S, Joseph G, Horo S, Danda D

Published 14 October 2010 Volume 2010:4 Pages 1173—1176


Review by Single anonymous peer review

Peer reviewer comments 2

Jayanthi Peter1, Sarada David1, George Joseph2, Saban Horo1, Debashish Danda3

1Department of Ophthalmology, Schell Eye Hospital, Vellore, India; 2Department of Cardiology, Christian Medical College Hospital, Vellore, India; 3Department of Clinical Immunology and Rheumatology, Christian Medical College Hospital, Vellore, India

Abstract: Takayasu arteritis is a relatively rare inflammatory arteritis that can be associated with ocular manifestations. We report four patients with proven Takayasu arteritis; two patients manifested hypoperfusive ocular manifestations of ocular ischemic syndrome and anterior ischemic optic neuropathy whilst two others had exudative retinal detachment and papilledema as a result of severe hypertension. The ischemic ocular manifestations were a result of hypoperfusion of the ocular structures due to occlusive arteritis of the aortic arch and its branches. The exudative retinal detachment and papilledema were manifestations of severe hypertension due to renal arterial involvement. Patients with Takayasu arteritis should be referred for ophthalmic assessment and screening for hypoperfusive and hypertensive manifestations.

Keywords: Takayasu, retinopathy, ocular ischemic syndrome, India

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.